ArticleJournal of the American Geriatrics Society2016
Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
Article in Journal of the American Geriatrics Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal.PharmacoEconomics - open · 2026Pooled it
- Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Pooled it
- Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.Human vaccines & immunotherapeutics · 2019Pooled it
- Article
- Article
- Review
- Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Article
- Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians.Journal of general internal medicine · 2021Article
- Review
- Pharmacists' Perspectives on Providing the Influenza Vaccine in Community Pharmacies: A Qualitative Study.Risk management and healthcare policy · 2020Article
- Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis.American journal of preventive medicine · 2019Article
- Exploring the potential public health benefits of universal influenza vaccine.Human vaccines & immunotherapeutics · 2019Article
- Article
- Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.Vaccine · 2017Article
- Reply to: Estimating the Full Value of High-Dose Influenza Vaccine.Journal of the American Geriatrics Society · 2017Article
- A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.Human vaccines & immunotherapeutics · 2017Review
- Age-Related Diseases and Clinical and Public Health Implications for the 85 Years Old and Over Population.Frontiers in public health · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectivesTo compare the cost-effectiveness of four influenza vaccines available in the United States for persons aged 65 and older: trivalent inactivated influenza vaccine (IIV3), quadrivalent inactivated influenza vaccine (IIV4), a more-expensive high-dose IIV3, and a newly approved adjuvanted IIV3.
designCost-effectiveness analysis using a Markov model and sensitivity analyses.
settingA hypothetical influenza vaccination season modeled according to possible U.S. influenza vaccination policies.
participantsHypothetical cohort of individuals aged 65 and older in the United States. MEASUREMENTS: Cost-effectiveness and public health benefits of available influenza vaccination strategies in U.S. elderly adults.
resultsIIV3 cost $3,690 per quality-adjusted life year (QALY) gained, IIV4 cost $20,939 more than IIV3 per QALY gained, and high-dose IIV3 cost $31,214 more per QALY than IIV4. The model projected 83,775 fewer influenza cases and 980 fewer deaths with high-dose IIV3 than with the next most-effective vaccine: IIV4. In a probabilistic sensitivity analysis, high-dose IIV3 was the favored strategy if willingness to pay is $25,000 or more per QALY gained. Adjuvanted IIV3 cost-effectiveness depends on its price and effectiveness (neither yet determined in the United States) but could be favored if its relative effectiveness is 15% greater than that of IIV3.
conclusionFrom economic and public health standpoints, high-dose IIV3 for adults aged 65 years and older is likely to be favored over the other vaccines, based on currently available data. The cost-effectiveness of adjuvanted IIV3 should be reviewed after its effectiveness has been compared with that of other vaccines and its U.S. price is established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.